When and How You Become Refractory to a Drug and How to Find the Best Next Treatment

Event Description
Many patients wonder how one becomes refractory to a drug, and how the specialist knows what the next best step is to take. How long should you let your numbers increase without making a change in treatment? When is it ok to let it ride and for how long? And with all the different options, how can you truly know what your "next best option" really is? Learn the answers to these questions and more as we hear from myeloma specialist Dr. Omar Nadeem from Dana Farber Cancer Institute.
Schedule & Agenda

Audrey introduces the agenda of the event and featured speaker Dr. Omar Nadeem.

Audrey introduces the agenda of the event and featured speaker Dr. Omar Nadeem.

Dr. Omar Nadeem talks about how one becomes refractory to a drug, and how the specialist knows what the next best step is to take.

Dr. Omar Nadeem talks about how one becomes refractory to a drug, and how the specialist knows what the next best step is to take.
Type your questions in the chat and we will answer them!
Type your questions in the chat and we will answer them!
Speakers & Moderators

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.

Dr. Nadeem completed his internal medicine residency training at Dartmouth-Hitchcock Medical Center and his hematology/oncology fellowship at the Warren Alpert Medical School of Brown University. He is board certified in internal medicine, hematology and medical oncology. He joined the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute in 2018. He is an Instructor in Medicine at Harvard Medical School and serves as the Clinical Director of Myeloma Cellular Therapies Program and Director of Myeloma and Plasma Cell Pathways at the Dana-Farber Cancer Institute. His clinical and research interests include studying the role of immunotherapy and cellular therapies in multiple myeloma, with particular focus on CAR T-cell therapy. He serves as a principal investigator of several clinical trials in smoldering multiple myeloma, newly diagnosed disease and relapsed and refractory multiple myeloma. He also attends in the Center of Prevention of Progression (CPOP) clinic at DFCI, which is focused on management of patients with precursor plasma cell disorders.
Join the Conversation
This event is part of the Disease Progression and Relapsed/Refractory group in HealthTree Connect, a social media platform for people with blood cancer. If you want to connect with other patients and caregivers and talk about this topic, join HealthTree Connect.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org







Get the Latest Multiple Myeloma Updates, Delivered to You.
By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.